Scottsdale Round Table - October 14, 2018 image

Scottsdale Round Table - October 14, 2018

Oct 14, 2018
09:00AM - 03:00PM MDT In the city timezone
Scottsdale, AZ
Scottsdale, AZ, USA
Overview

On October 14, 2018, a Myeloma Crowd Round Table meeting was held in Scottsdale, AZ at the Mayo Clinic featuring three myeloma experts, including:

  • Rafael Fonseca, MD, Mayo Clinic Scottsdale
  • Gareth Morgan, MD, FRCP, FRCPath, PhD, University of Arkansas Myeloma Institute
  • Leif Bergsagel, MD, PhD, Mayo Clinic Scottsdale

Thanks to our Sponsors

User uploaded media

User uploaded media

User uploaded media

Highlights
Speakers & Moderators
Healthtree contact Rafael Fonseca, MD

Rafael Fonseca, MD

Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, interim Executive Director of the Mayo Clinic Comprehensive Cancer Center…

Rafael Fonseca, MD, is the Getz Family Professor of Cancer, Professor of Medicine, Chief Innovation Officer, and a consultant in the Division of Hematology/Oncology at the Mayo Clinic in Arizona. He is a member of the Mayo Clinic Board of Governors and Board of Trustees. He earned his MD at Universidad Anahuac, Mexico. He completed a residency in Internal Medicine at the University of Miami, FL, and a fellowship in Hematology and Medical Oncology at Mayo Graduate School of Medicine, Rochester, MN. He was named a Clinical Investigator for the Damon Runyon Cancer Research Fund. Dr Fonseca’s practice and research have focused on the diagnosis and treatment of plasma cell disorders. He leads the multiple myeloma team in its efforts to develop a better understanding of the disease and its impact on patients. In his laboratory, Dr Fonseca has led his team of researchers to better understand the genetic nature of malignant plasma cells, real world evidence analysis, myeloma bone disease, prognostic markers, pharmacoeconomics and development of new therapies for the disease. He is an active participant and leader of myeloma clinical trials. He also has served as consultant to multiple companies including AbbVie, Adaptive Biotechnologies, Amgen, Apple, BMS, GSK, Janssen, Karyopharm, Pfizer, Regeneron, and Sanofi. He is a member of the Scientific Advisory Board of Caris Life Sciences, Ryght, Fortvita and Xenagos. He is a member of the Board of Directors for Antengene. He holds the patent for FISH prognostication in myeloma. He has over 400 peer reviewed publications with an associated H index of 135 with 73,278 citations (Google Scholar October 2026). Throughout his training and career, Dr Fonseca has received numerous awards and honors, including the Damon Runyon Clinical Investigator Award, and the International Waldenström Macroglobulinemia Research Award. He is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at his institution. He was awarded in 2023 the Cyril-Rozman prize by the Spanish Society of Hematology and Hematotherapy. He was awarded a Doctor honoris causa by the Universidad de San Pablo, Argentina in February 2023. He was inducted into the Giants of Cancer Care in 2024. Dr Fonseca holds memberships and has served in positions for organizations such as the ASCO, ASH and the International Myeloma Society. His research has been funded by the National Cancer Institute (R01, P01, SPORE, CPTAC U01), the Leukemia & Lymphoma Society, the Multiple Myeloma Research Foundation, and the Damon Runyon Cancer Research Fund, Paula and Rodger Riney Foundation and others. Dr Fonseca serves as reviewer and in editorial capacities for medical publications including Blood, Lancet, Nature Medicine, Cancer Cell, Leukemia, and the New England Journal of Medicine, among others. He has given many national and international presentations as a visiting professor.
Healthtree contact Gareth Morgan, MD, PhD

Gareth Morgan, MD, PhD

Gareth Morgan, MD, PhD, is Director of Multiple Myeloma Research at NYU Langone Perlmutter Cancer Center in New York, NY. He is an internationally recognized clinician-scientist in the molecular genetics of blood cell cancers and myeloma treatment. He has a particular focus on diagnostic prevention and treatment strategies for high-risk and relapsed/refractory myeloma. Dr. Morgan is doing influential work on the characterization of the myeloma genome, defining specific subsets of the disease that have prognostic importance, and developing personalized therapeutic strategies targeted to each subtype. He is also engaged in advanced research in molecular diagnostics, drug development, and clinical trials. His research aims to cure myeloma and to reduce side effects by targeting treatment to the biology underlying each patient’s cancer. Prior to leading the Perlmutter Cancer Center’s myeloma program, Dr. Morgan was Professor of Medicine and Director of the Myeloma Institute at the University of Arkansas for Medical Sciences and Professor of Hematology and Director of the Centre for Myeloma Research at the Royal Marsden NHS Foundation Trust and The Institute of Cancer Research in London, Europe’s largest comprehensive cancer institute. He is also a founding director of the European Myeloma Network and has authored more than 500 peer-reviewed journals. Dr. Morgan received his doctorate on the genetics of leukemia from the University of London in 1991 and his bachelor of medicine in 1981 from the Welsh National School of Medicine. His post graduate medical training was completed in Wales and at the Royal Postgraduate Medical School in London.
Healthtree contact Leif Bergsagel, MD

Leif Bergsagel, MD

Leif Bergsagel, MD, is among the top researchers in the world who studies the molecular pathogenesis of multiple myeloma. His laboratory is focused on understanding the molecular events that lead to the development of MGUS and its progression to multiple myeloma. The research of Dr. Bergsagel and his colleagues has identified important subtypes of multiple myeloma that respond differently to treatment, are associated with different survival rates and form the basis for a risk-adapted approach to therapy. Using insights gained from an understanding of the genetic events that lead to the development of multiple myeloma, Dr. Bergsagel’s team have generated a mouse model of the disease. This model is being used to screen novel agents for their anti-myeloma activity. Dr. Bergsagel’s team have cloned more than 35 translocation breakpoints and identified five frequent translocation partners that are present in almost one-half of patients with multiple myeloma. They are now working to identify and clone various translocation breakpoints in order to clarify their roles in the development of multiple myeloma. Another focus is on the MYC oncogene that appears in some patients to cause the progression of MGUS to myeloma. Prior to joining the faculty at the Mayo Clinic, Dr. Bergsagel was on the medical faculty of the University of Toronto and a Medical Staff Fellow at the National Cancer Institute. He was a junior resident at the Stanford University Medical Center, completed his internship at Sunnybrook Medical Centre, and received his MD from the University of Toronto. He is a member of the National Institutes of Health Basic Mechanisms of Cancer Therapeutics Study Section and the American Society for Clinical Investigations. His honors include lectureships at Ohio State University, Hammersmith Hospital in London, England, and the Daniel E. Bergsagel visiting professorship at the Ontario Cancer Institute in Canada. In 2009 he was honored with the Robert A. Kyle Mayo Clinic Distinguished Investigator Award.